Academic Journal
Q1Expert Review of Anti-Infective Therapy
About Expert Review of Anti-Infective Therapy
About Expert Review of Anti-Infective Therapy
Expert Review of Anti-Infective Therapy is a peer-reviewed scholarly journal published by Taylor and Francis Ltd. (United Kingdom). It focuses on Q1. Publication coverage spans 2003-2026.
Key indicators: ISSN 1478-7210, 1744-8336; H-index 110.
Understanding This Journal's Metrics
Journal metrics help researchers assess fit, but they must be interpreted in context:
- H-index (110): Exceptionally high — 110 articles have each been cited at least 110 times. This indicates deep, sustained influence in the field.
Publishing in Expert Review of Anti-Infective Therapy
An established venue in its field. The journal welcomes solid, well-executed research. Ensure your manuscript fits the stated scope and follows author guidelines carefully.
- Scope fit: Confirm your research aligns with Q1. Off-scope manuscripts are typically desk-rejected quickly.
- Author guidelines: Follow formatting, reference style, and article-type requirements exactly — non-compliant manuscripts may be returned without review.
- Submission: Submit via the official journal website.
Is This Journal Right for Your Paper?
- Audience match: Will the journal's readers cite and build on your findings?
- Timeline: Higher-tier journals mean longer review and higher rejection risk. Balance prestige against your schedule.
- Indexing: Confirm indexing in Web of Science, Scopus, and PubMed (if biomedical) meets your institutional requirements.
- Open access needs: Check funder mandates and whether the journal offers compliant OA options.
Frequently Asked Questions
What is the ISSN of Expert Review of Anti-Infective Therapy?
1478-7210, 1744-8336.
Who publishes Expert Review of Anti-Infective Therapy?
Taylor and Francis Ltd..
What are Expert Review of Anti-Infective Therapy's metrics?
H-index 110.
Where do I submit to Expert Review of Anti-Infective Therapy?
Via the official website.
Is Expert Review of Anti-Infective Therapy peer-reviewed?
Yes — it is a peer-reviewed scholarly journal indexed in major academic databases.
Source-backed journal facts
Topics in published research
Antibiotic Resistance in Bacteria; Antibiotic Use and Resistance; Antibiotics Pharmacokinetics and Efficacy; Pneumonia and Respiratory Infections; Antifungal resistance and susceptibility; Antimicrobial Resistance in Staphylococcus.
OpenAlex classifies topics from published works. These topics are not the publisher’s official aims and scope.
Source: OpenAlex source record. Retrieved 2026-10-03. Source record updated 2026-10-02. OpenAlex metrics are different from SCImago metrics and the Clarivate Journal Impact Factor.
Journal Metrics
Quartile, SJR and the listed SCImago H-index use the 2025 imported SCImago dataset. A quartile may vary by subject category. Values without a source or reporting year are unverified historical entries. Verify the current Journal Impact Factor with Clarivate or the publisher before using it.
Aims & Scope
The publisher’s official aims and scope have not yet been verified for this profile. Use the journal website to check subject fit and accepted article types before submitting.
Recent Research Articles
Latest publications matched automatically by ISSN.
Antibiotic prophylaxis and empirical therapy for intra-abdominal infections: a systematic review and network meta-analysis
Pooja Singh, Malvika Sharma, Khyati Gupta, Vikas Dhiman et al.
2026-10-14 · DOI: 10.1080/14787210.2026.2746348Effectiveness of Remdesivir in individuals with confirmed Omicron variant: a meta-analysis of cohort studies
Hila Asham, Kosar Kouchari, Hossein Bannazadeh Baghi, Samaneh Dousti et al.
2026-10-12 · DOI: 10.1080/14787210.2026.2749496Evaluating the potential of treatment options for chronic hepatitis B
Shang-Chin Huang, Jia-Horng Kao
2026-10-12 · DOI: 10.1080/14787210.2026.2749497Advances needed for improving leprosy diagnosis in Brazil
Sálvia Cely Cerqueira Carvalho, Leonardo Lopes-Luz, Victor Santana Santos
2026-10-08 · DOI: 10.1080/14787210.2026.2744223A systematic review of the clinical pharmacokinetics of fluconazole in healthy and diseased populations
Tahir Saleem, Khadija Ameen, Muhammad Fawad Rasool, Faleh Alqahtani et al.
2026-10-07 · DOI: 10.1080/14787210.2026.2744221Better incorporating real world evidence into anti-infective therapy development
Milo Gatti, Federico Pea
2026-10-06 · DOI: 10.1080/14787210.2026.2744572Is fluoroquinolone use controversial?
Joseph M. Blondeau, Glenn S. Tillotson
2026-09-29 · DOI: 10.1080/14787210.2026.2740110Zika virus in the Americas: transmission dynamics, clinical lessons, and future risk
Natalia Guimaraes, Talita Adelino, Luiz Carlos Junior Alcantara, Ana Maria Bispo de Filippis et al.
2026-09-29 · DOI: 10.1080/14787210.2026.2741271Clinical use of dalbavancin in Canada: the CLEAR study final results
George G. Zhanel, Michael Silverman, Janhavi Bhalla, Melanie Baxter et al.
2026-09-29 · DOI: 10.1080/14787210.2026.2740112Emerging therapies for Candidozyma auris ( Candida auris) : current landscape and future directions
Liyang Zhang, Lewis Oscar Felix, Eleftherios Mylonakis
2026-09-28 · DOI: 10.1080/14787210.2026.2740114Measles resurgence in Europe: a public health setback
Maria Antonia De Francesco, Eugenia Quiros-Roldan
2026-09-28 · DOI: 10.1080/14787210.2026.2740115Novel options for the management of C. difficile : a look into the future
Guido Granata, Nicola Petrosillo, Fabrizio Taglietti
2026-09-26 · DOI: 10.1080/14787210.2026.2739273Advances in combination therapies for serious infections due to multidrug-resistant gram-negative bacilli
Luca Mezzadri, Abi Manesh, Ya-Ting Chang, Kim Anh Nguyen et al.
2026-09-20 · DOI: 10.1080/14787210.2026.2730311Novel potential treatment options for infections caused by multi-drug and extensively drug-resistant Neisseria gonorrhoeae strains
Susanne Jacobsson, Magnus Unemo
2026-09-17 · DOI: 10.1080/14787210.2026.2733617Resistance of uropathogens to fosfomycin: an evaluation of the published evidence
Konstantinos Μ. Katsikas, Panagiota Poziou, Panagiotis Stavroulakis, Paraskevi Maria Paliogianni et al.
2026-09-16 · DOI: 10.1080/14787210.2026.2733621Ten-year trends in sepsis-causing multidrug-resistant pathogens: a nationwide multicenter laboratory-based surveillance in Pakistan (2013–2022) and predictive forecasting of antimicrobial resistance (2030)
Muhammad Usman Qamar, Gohar Zaman, Muhammad Rizwan, Rizwan Uppal et al.
2026-09-16 · DOI: 10.1080/14787210.2026.2734514Early versus delayed IV-to-oral antibiotic transition: clinical deterioration after oral switch and variation across regimen pathways
Khalid Orayj, Azfar Athar Ishaqui, Salman Ashfaq Ahmad, Sultan M. Alshahrani et al.
2026-09-09 · DOI: 10.1080/14787210.2026.2729395Pan-TB regimens: too good to be true?
Stephen J. Aston, Geraint R. Davies
2026-09-08 · DOI: 10.1080/14787210.2026.2719692Methicillin-resistant Staphylococcus aureus treatment and control in neonates: lessons learned - a Vietnam perspective
Jennifer Le, Tavin Sayles, Duy Kieu Nguyen, Anh Viet Nguyen et al.
2026-09-08 · DOI: 10.1080/14787210.2026.2726969A 12-year trend of antimicrobial resistance among ESKAPEEc organisms isolated from blood cultures in a large private medical diagnostic laboratory network in Malaysia (2013–2024)
Omotayo Fatokun, Ali Haider Mohammed, Chuan Sheng Yap, Ariza Adnan et al.
2026-09-08 · DOI: 10.1080/14787210.2026.2729403Reviews
Community Reviews
Version History
October 9, 2026 at 9:06 pm
October 2, 2026